Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: A method is provided that allows the sulfur component concentration in gasoline to be estimated to high precision. The measuring method of the disclosure is a method of measuring the concentration of sulfur components in gasoline that contains sulfur components and aromatic components. The measuring method of the disclosure comprises: (A1) removing a portion of the gasoline by gasification to lower the proportion of the aromatic component concentration with respect to the sulfur component concentration in the gasoline, (A2) measuring values related to the refractive index of the gasoline, and (A3) measuring the sulfur component concentration in the gasoline based on the values related to the refractive index.

Abstract: In one embodiment, the present invention provides an anti-cancer-associated non-tumor cell agent. In one embodiment, the present invention relates to an anti-cancer-associated non-tumor cell agent comprising an oncolytic virus comprising a p53 gene. In one embodiment, the present invention relates to an anti-cancer-associated non-tumor cell preparation comprising a recombinant virus comprising: a first gene cassette containing a telomerase reverse transcriptase promoter, an E1A gene, an IRES sequence and an E1B gene; and a second gene cassette containing a promoter and a p53 gene.

Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: Provided are a determination method and a kit both for determining the possibility of the occurrence of deterioration of a renal function in the future. A method according to one aspect of the present invention involves a step of determining the level of Gal?1-3GalNAc and/or Sia?2-6Gal/GalNAc in a sample collected from a subject. A kit according to one aspect of the present invention includes a lectin capable of binding to Gal?1-3GalNAc and/or Sia?2-6Gal/GalNAc.

Abstract: The present invention provides a novel compound that can be used as a lactate dehydrogenase inhibitor or an active ingredient of a medicament such as an antiepileptic agent and an anti-cancer agent, and particularly, provides a novel compound excellent in metabolic stability. The novel compound according to the present invention is a compound represented by the following formula (1). In formula (1), R represents any substituent (for example, a monovalent substituent of an aromatic or non-aromatic 3 to 14-membered ring which may be unsubstituted or substituted and monocyclic or polycyclic), Ra, Rb, Rc, Rd, Re, Rf, Rg, Rh and Ri each represent a hydrogen atom or any substituent (for example, Ra to Ri are all hydrogen atoms, or Re, Rf, Rg, Rh and Ri are hydrogen atoms and at least one of Ra, Rb, Rc and Rd is any substituent).

Abstract: Amyotrophic lateral sclerosis (ALS) is a life-threatening neurodegenerative disease characterized by the progressive loss of motor neurons. Muse cells are endogenous reparative pluripotent-like stem cells distributed to various tissues. Once intravenously injected, such cells, upon sensing sphingosine-1-phosphate produced by damaged cells, settle selectively on damaged sites, and after homing, can exhibit multiphase effects including natural differentiation into tissue-protecting and tissue-reconstructing cells. In the present invention, with G93A-Tg mice serving as an ALS model, human Muse cells injected intravenously successfully homed into the lumbar cord, mainly at the pia mater and the lower white matter, and expressed glial-like forms and GFAP. Meanwhile, no such homing or differentiation was observed in the case of human mesenchymal stem cells (MSCs), and, rather, MSCs were found distributed to the lungs.

Abstract: The present invention is to provide a method for producing a cartilage tissue which comprises a step of providing a substrate for producing cell aggregates provided with a plurality of spots comprising a copolymer containing recurring units derived from monomers represented by the following formulae (I) and (II): [wherein Ua1, Ua, Ra1, Ra2 and Rb are as described in the specification and claims] on a substrate having an ability to suppress adhesion of cells; a step of seeding human cartilage progenitor cells which are positive for PRRX1 protein and derived from pluripotent stem cells on the substrate; a step of producing cell aggregates by culturing the cells; and a step of culturing the aggregates to produce a cartilage tissue.

Abstract: A control method, a controller, and a control system including a converter and the controller are provided to improve load responsiveness of control by the converter. The converter has a primary circuit that includes a voltage generation circuit for generating a square wave and a resonant circuit for converting a waveform of the generated square wave, and a secondary circuit that is electromagnetically coupled to the primary circuit and that generates an induced electromotive force. The controller controls the voltage generation circuit by a control target power factor. To implement power factor-based control, the controller controls the voltage generation circuit, based on a derived power factor derived from an active power and an apparent power relevant to the resonant circuit in the primary circuit or a derived power factor derived from a phase of the primary circuit.

Abstract: An RNA methyltransferase inhibitor comprising sulfonamide-based compounds and/or pyrazoline-based compounds is provided

Abstract: The present invention provides an inflammatory pulmonary disease agent capable of effectively preventing and/or treating an inflammatory pulmonary disease, and specifically relates to a prophylactic and/or therapeutic agent for an inflammatory pulmonary disease containing, as an active ingredient, an antibody or an antibody fragment having antigen-binding activity for an S100A8/A9 heterodimer. The inflammatory pulmonary disease can be effectively prevented and/or treated by blocking interaction between S100A8/A9 and a group of receptors therefor. Specifically, the inflammatory pulmonary disease can be effectively prevented and/or treated by: blocking interaction between S100A8/A9 and RAGE, which is a receptor therefor, to suppress: the expression of NF-?B, which is a transcription factor present downstream of RAGE and induces the expression of various inflammatory cytokines; the proliferation of activated fibroblasts; and the differentiation of activated fibroblasts into myofibroblasts.

Abstract: Provided is a positive electrode material which can impart a lithium secondary battery with excellent low temperature output characteristics, excellent high temperature cycle characteristics and excellent durability against high voltage. A positive electrode material of a lithium secondary battery disclosed here includes a positive electrode active substance particle, a Li-free first coating at the surface of the positive electrode active substance particle, and a Li-containing second coating at the surface of the positive electrode active substance particle. The first coating contains a titanium oxide represented by TiO2 or TinO2n-1, wherein n is an integer of 3 or more. The second coating contains a composite oxide containing Li and Ti, wherein the ratio of the number of atoms of Li relative to the number of atoms of Ti is at least 0.1 and at most 3.

Abstract: A positive electrode material which is used in a positive electrode of a lithium ion secondary battery disclosed here includes a positive electrode active material including a compound capable of storing and releasing lithium ions, a first coating material disposed on at least a part of the surface of the positive electrode active material, and a second coating material disposed on at least a part of the surface of the positive electrode active material. The positive electrode material is characterized in that the first coating material contains a nickel oxide having a rock salt structure, and the second coating material contains a titanium oxide.

Abstract: A control method, a controller, and a control system including a converter and the controller are provided to improve load responsiveness of control by the converter. The converter has a primary circuit that includes a voltage generation circuit for generating a square wave and a resonant circuit for converting a waveform of the generated square wave, and a secondary circuit that is electromagnetically coupled to the primary circuit and that generates an induced electromotive force. The controller controls the voltage generation circuit by a control target power factor. To implement power factor-based control, the controller controls the voltage generation circuit, based on a derived power factor derived from an active power and an apparent power relevant to the resonant circuit in the primary circuit or a derived power factor derived from a phase of the primary circuit.

Abstract: Provided is a method of assisting the detection of nonalcoholic steatohepatitis (NASH), which is far less invasive than liver biopsy and is based on simple operations that do not require skilled technical personnel. The present invention is a method of assisting the detection of NASH, which includes: a) measuring the amount of LDL-TG contained in a test blood sample isolated from a living body; b) measuring the amount of at least one component selected from the group consisting of LDL-C, LDL subfraction-C, IIDL-C, HDL subfraction-C, ApoB, ApoE, total cholesterol, ALT, and AST contained in the test blood sample; and c) determining the possibility of developing and/or having NASH by using the amount of LDL-TG in combination with the amount of the at least one component.

Abstract: A positive electrode imparts secondary battery with low temperature output characteristics, high temperature cycle characteristics and durability against high voltage. A positive electrode of secondary battery includes positive electrode current collector and positive electrode active substance layer on positive electrode current collector. The positive electrode active substance layer contains positive electrode active substance particles and oxide particles which are dispersed in positive electrode active substance layer as separate particles from positive electrode active substance particles. The positive electrode active substance particles each include coating of titanium-containing compound at the surface. The titanium-containing compound in coating is at least one compound selected from group consisting of TiO2, TinO2n?1, wherein n is integer of 3 or more, and oxides containing Li and Ti.

Abstract: The present invention provides a limb bud mesenchymal cell population, which is derived from mammalian lateral plate mesoderm cells, and is PRRX1 protein-positive.

Abstract: The present invention relates to a method including culturing a C1 compound-assimilating bacterium, which is a methylotroph, and/or a yeast by using a medium comprising, for example, a C1 compound and/or glycerol as a carbon source, to thereby produce EGT.

Abstract: An object provide a technique capable of measuring temperature on the basis of optically detected magnetic resonance with higher precision, The object is achieved by a method for measuring the temperature of an object on the basis of optically detected magnetic resonance of an inorganic fluorescent particle, including (a) irradiating the object, containing the inorganic fluorescent particle with each of multiple microwaves having different frequencies, (b) measuring the fluorescence intensities of the inorganic fluorescent particle with individual photon counters at the time of irradiation of respective microwaves, (c) correcting the fluorescence intensities on the basis of dependencies in the number of pulse measurements between the photon counters and (d) Calculating the temperature of the object on the basis of the obtained fluorescence intensity with the correction values.

Abstract: One aspect of the present disclosure relates to a method for manufacturing a spun yarn made of carbon nanotubes. The method includes: a spun yarn precursor ? production step of producing a spun yarn precursor ? by pulling a plurality of carbon nanotubes from a carbon nanotube forest and spinning the carbon nanotubes while applying a tension of 6 mN or less per centimeter of a width of the carbon nanotube forest to the carbon nanotubes; a spun yarn precursor ? production step of producing a spun yarn precursor ? by applying a higher tension than in the spun yarn precursor ? production step to the spun yarn precursor ? to densify the spun yarn precursor ?; and a spun yarn production step of producing the spun yarn by electrically heating the spun yarn precursor ? while applying a tension to the spun yarn precursor ?.